Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 821,68 € (-6,36 %). Medianen er 794,79 € (-9,42 %).
| Køb |
34 |
| Behold |
15 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Regeneron exceeds Q3 expectations significantly and hits 52-week high
Regeneron reports Q3 revenue up 36% to $5.1 billion and adjusted earnings per share of $20.07 versus $16.24 expected. Collaboration revenue with Sanofi, mainly from Dupixent, rose 68% to $2.72 billion. Strong contributions also came from Libtayo and the higher-dose Eylea, which boosted revenues by $550 million and $699 million respectively; the stock rises about 8% in premarket trading. » Mere på deraktionaer.de
Regeneron highlights EYLEA HD momentum, Dupixent growth and upcoming pipeline catalysts
Regeneron reported double-digit revenue and earnings growth with EYLEA HD comprising ~60% of EYLEA franchise sales and expected low- to mid-teens sequential demand growth in Q3 and Q4 despite biosimilar pressure. Dupixent is annualizing at about $24 billion and Libtayo grew over 30% year-over-year, strengthening position in U.S. lung cancer. Management flagged near-term catalysts including an FDA decision for cemdisiran in generalized myasthenia gravis in November, PNH data in Q4, Phase III and Phase II readouts in Factor XI and MASH programs, and melanoma data later this year. The company repurchased roughly $2 billion of stock in H1 and continues to prioritize pipeline funding, business development, dividends and buybacks. » Mere på finance.yahoo.com
Regeneron continues to rely on Dupixent for growth and advances pipeline and production expansion
Regeneron sees Dupixent as its main growth driver and expects about USD 22 billion for its US business in 2026, assuming a market penetration of roughly 15–20% in atopic dermatitis. EYLEA HD is gaining market share in the anti‑VEGF segment, while biosimilars are likely to intensify competition in 2026/2027. Key pipeline milestones include cemdisiran with an FDA decision for generalized myasthenia gravis in November 2026 and PNH and GA data at the end of 2026; several DUPIXENT follow‑on programs are planned. Regeneron is expanding production capacity in northern New York and is prioritizing capital allocation for internal research, selective acquisitions and share buybacks. » Mere på de.investing.com
American Century sells Regeneron, cites limited upside from sluggish commercialization
American Century Investments' Focused Dynamic Growth Fund disclosed it sold its Regeneron position, saying longstanding confidence in the company's research platform has been undermined by weak commercialization of its macular degeneration treatment and limited appreciation potential. The fund redeployed proceeds into names it views as having better upside, amid a quarter where growth and AI stocks led performance while healthcare lagged. Hedge fund ownership of Regeneron also declined slightly quarter‑over‑quarter. » Mere på finance.yahoo.com
Regeneron announces broad-based growth and deep pipeline at Wells-Fargo conference
At the Wells-Fargo Healthcare Conference, Regeneron presented a strategy for broader growth, stronger operational execution and an expanded product pipeline. In Q2 2026 the company recorded double-digit revenue and earnings gains, driven by record sales of EYLEA HD, DUPIXENT and LIBTAYO; DUPIXENT reached an annualized run rate of USD 24 billion. Regeneron identified several near-term catalysts, including the PDUFA date for Cemdisiran in generalized myasthenia gravis and a regulatory filing for an EYLEA-HD prefilled syringe by year-end. Management emphasized the long-term advantage of its linked genetics and proteomics database for AI-powered drug discovery and signaled openness to selective business collaborations with Sanofi at disciplined valuations. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 4,52 mia. | 41,18 % |
| Bruttofortjeneste | 4,01 mia. | 45,57 % |
| Nettoresultat | 1,72 mia. | 38,28 % |
| EBITDA | 2,13 mia. | 30,40 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 89,77 mia. € |
Antal aktier | 103,43 mio. |
Højeste/laveste i 52 uger | 900,82 € - 537,30 € |
Udbytteafkast | 0,37 % |
Udbytte TTM | 3,18 € |
Næste udbytte | 0,85 € |
Beta | 0,24 |
P/E (PE Ratio) | 20,35 |
PEG (PEG Ratio) | 2,52 |
K/I (PB Ratio) | 2,90 |
P/S (PS Ratio) | 5,85 |
Virksomhedsprofil
Regeneron Pharmaceuticals, Inc. opdager, opfinder, udvikler, fremstiller og kommercialiserer lægemidler til behandling af forskellige sygdomme på verdensplan. Virksomhedens produkter omfatter EYLEA-injektion til behandling af våd aldersrelateret makuladegeneration og diabetisk makulaødem; myopisk choroidal neovaskularisering; og diabetisk retinopati samt makulaødem efter retinal venookklusion, herunder makulaødem efter central retinal venookklusion og makulaødem efter grenretinal venookklusion. Virksomheden leverer også Dupixent-injektion til behandling af atopisk dermatitis og astma hos voksne og børn; Libtayo-injektion til behandling af metastatisk eller lokalt fremskreden cutant planocellulært karcinom; Praluent-injektion til heterozygot familiær hyperkolesterolæmi eller klinisk aterosklerotisk kardiovaskulær sygdom hos voksne; REGEN-COV til covid-19; og Kevzara-opløsning til behandling af reumatoid artritis hos voksne. Derudover tilbyder virksomheden Inmazeb-injektion til infektion forårsaget af Zaire ebolavirus; ARCALYST-injektion til cryopyrin-associerede periodiske syndromer, herunder familiært koldt autoinflammatorisk syndrom og Muckle-Wells syndrom; og ZALTRAP-injektion til intravenøs infusion til behandling af metastatisk colorektal cancer; og udvikler produktkandidater til behandling af patienter med øjen-, allergiske og inflammatoriske, kardiovaskulære og metaboliske, infektiøse og sjældne sygdomme samt cancer, smerte og hæmatologiske tilstande. Virksomheden har samarbejds- og licensaftaler med Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; og Kiniksa Pharmaceuticals, Ltd., samt en aftale med det amerikanske Department of Health and Human Services, samt med Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; og AstraZeneca PLC. Virksomheden blev stiftet i 1988 og har hovedkontor i Tarrytown, New York.
| Navn | Regeneron Pharmaceuticals |
| CEO | Leonard S. Schleifer |
| Hjemsted | Tarrytown,
ny USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Bioteknologi |
| Børsnotering | 12.09.2017 |
| Medarbejdere | 15.410 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | REGN |
London Stock Exchange | 0R2M.L |
Frankfurt | RGO.F |
Düsseldorf | RGO.DU |
Hamburg | RGO.HM |
Milan | 1REGN.MI |
London | 0R2M.L |
SIX | RGO.SW |
München | RGO.MU |
Wien | REGN.VI |
XETRA | RGO.DE |